Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis

被引:0
|
作者
Sloan, RP
Schwartz, MM
Korbet, SM
Borok, RZ
机构
[1] RUSH MED COLL,DEPT MED,CHICAGO,IL 60612
[2] RUSH MED COLL,DEPT PATHOL,CHICAGO,IL 60612
[3] GEORGE WASHINGTON UNIV,WASHINGTON,DC
[4] WILLIAM BEAUMONT HOSP,ROYAL OAK,MI 48072
[5] FRANCIS SCOTT KEY MED CTR,BALTIMORE,MD 21224
[6] MAYO CLIN,ROCHESTER,MN
[7] CLEVELAND CLIN,CLEVELAND,OH 44106
[8] UNIV COLORADO,DENVER,CO 80202
[9] HENRY FORD HOSP,DETROIT,MI 48202
[10] UNIV IOWA,IOWA CITY,IA
[11] NORTHWESTERN UNIV,EVANSTON HOSP,EVANSTON,IL 60201
[12] TUFTS UNIV,NEW ENGLAND MED CTR,BOSTON,MA 02111
[13] MED COLL WISCONSIN,MILWAUKEE,WI 53226
[14] NEW YORK MED COLL,VALHALLA,NY 10595
[15] W VIRGINIA UNIV,MORGANTOWN,WV 26506
来源
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 1996年 / 7卷 / 02期
关键词
lupus; membranous glomerulonephritis; pathology; prognosis; survival;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
The pathology of membranous glomerulonephritis (MGN) in patients with systemic lupus erythematosus (SLE) may be complicated by superimposed glomerular inflammation and/or necrosis, This retrospective study examined whether various histologic patterns of glomerulonephritis (GN) seen on renal biopsy impact upon the prognosis of these patients. Clinical parameters at the time of biopsy were also studied, to determine which might serve as risk factors associated with renal and patient outcome. On the basis of renal biopsy findings, patients were stratified into three pathological study groups by using the World Health Organization (WHO) classification (11). Thirty-six patients had ''pure'' SLE MGN without (WHO Va) or with (WHO Vb) mesangial hypercellularity. Fifteen patients had SLE MGN with segmental endocapillary proliferation and/or necrosis in < 50% of glomeruli (WHO Vc < 50%). Twenty-eight patients had SLE MGN with endocapillary proliferation and/or necrosis in greater than or equal to 50% of glomeruli (MGN with segmental proliferation and/or necrosis in > 50%, WHO Vc greater than or equal to 50%, or MGN with superimposed diffuse endocapillary proliferation, WHO Vd), There were no significant differences in sex, age, or race among patients in the three study groups. There was a trend for increasing serum creatinine concentration, urine protein excretion, and diastolic blood pressure, and decreasing the third component of serum complement (C3) to be associated with increasing glomerular inflammation, and these differences were significant when Vc greater than or equal to 50% and Vd was compared with Va and Vb (P < 0.05). The 5- and 10-yr actuarial survival rates without reaching the study outcomes of death or renal replacement therapy for the three study groups were 86, 72, and 49% and 72, 48, and 20% respectively, and the differences between Va and Vb and Vc > 50% and Vd were significant (P < 0.05), SLE MGN has a heterogeneous course and outcome, and this variability is related to the extent and degree of glomerulonephritis seen on renal biopsy. The only clinical factor with an independent risk of reaching a study outcome was elevation of the initial serum creatinine concentration (Cox regression analysis). This predictive value appears to apply only to patients with the most severe forms of glomerulonephritis, suggesting that they may have a different natural history and/or a response to therapy than SLE MGN with less widespread glomerular inflammation and/or necrosis.
引用
收藏
页码:299 / 305
页数:7
相关论文
共 50 条
  • [21] Systemic Lupus Erythematosus Outcome Measures for Systemic Lupus Erythematosus Clinical Trials
    Tofighi, Taraneh
    Morand, Eric F.
    Touma, Zahi
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2021, 47 (03) : 415 - 426
  • [22] Long-term follow-up of Iranian male patients with systemic lupus erythematosus
    Abbas Smiley
    Mohammad Matinfar
    Alimohammad Fatemi
    Clinical and Experimental Medicine, 2023, 23 : 3399 - 3406
  • [23] Long-term outcomes in systemic lupus erythematosus: trends over time and major contributors
    Arnaud, Laurent
    Tektonidou, Maria G.
    RHEUMATOLOGY, 2020, 59 : 29 - 38
  • [24] Long-Term Outcome of Lupus Nephritis in Asian Indians
    Dhir, Varun
    Aggarwal, Amita
    Lawrence, Able
    Agarwal, Vikas
    Misra, Ramnath
    ARTHRITIS CARE & RESEARCH, 2012, 64 (05) : 713 - 720
  • [25] Septic shock among patients with systemic lupus erythematosus: Short and long-term outcome. Analysis of a French nationwide database
    Mageau, Arthur
    Sacre, Karim
    Perozziello, Anne
    Ruckly, Stephane
    Dupuis, Claire
    Bouadma, Lila
    Papo, Thomas
    Timsit, Jean-Francois
    JOURNAL OF INFECTION, 2019, 78 (06) : 432 - 438
  • [26] Subsequent progression to membranous glomerulonephritis following exacerbation of urticarial rash in systemic lupus erythematosus: Report of 2 cases
    Suzuki, K
    Tanaka, H
    Nakahata, T
    Fukuyama, Y
    Ito, E
    Waga, S
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (04): : 293 - 298
  • [27] Fibrillary glomerulonephritis in a patient with systemic lupus erythematosus with no evidence of lupus nephritis
    Whelband, Matthew Carl
    Willingham, Tom
    Thirunavukkarasu, Sathiamalar
    Patrick, Jean
    BMJ CASE REPORTS, 2023, 16 (02)
  • [28] Long-Term Hydroxychloroquine Therapy and Risk of Coronary Artery Disease in Patients with Systemic Lupus Erythematosus
    Yang, Deng-Ho
    Leong, Pui-Ying
    Sia, Sung-Kien
    Wang, Yu-Hsun
    Wei, James Cheng-Chung
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (06)
  • [29] Psychosis as a manifestation in systemic lupus erythematosus: treatment and long-term results. number of cases
    Rodarte-Gallegos, Maria Joselin
    Ramos-Sanchez, Ma . Azucena
    Mejia-Holguin, Yadhira
    Becerra-Marquez, Ariana Maia
    Ortiz-Trevino, Luciano
    REUMATOLOGIA CLINICA, 2024, 20 (10): : 567 - 569
  • [30] Evaluation of corneal safety in systemic lupus erythematosus patients undergoing long-term hydroxychloroquine treatment
    Caglayan, Mehtap
    Akyol, Lutfi
    Balci, Mehmet Ali
    Oncul, Hasan
    Alakus, Mehmet Fuat
    Dag, Umut
    CUTANEOUS AND OCULAR TOXICOLOGY, 2021, 40 (01) : 21 - 25